Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Metabolism. 2017 Oct 3;78:155–166. doi: 10.1016/j.metabol.2017.09.014

Figure 3. Effects of rosiglitazone and metformin treatment on serum ApoJ levels in subjects with type 2 diabetes.

Figure 3

All subjects (n=17) underwent a 2-step 5-hour hyperinsulinemic-euglycemic clamp and blood was drawn before and at the end of the clamp. (a) Serum ApoJ protein in T2D subjects treated with rosiglitazone or metformin. Each lane in the blot represents a different subject. The immunoblots shown are representative of three blots. (b) Bars show densitometric quantitation of serum ApoJ from T2D subjects with rosiglitazone or metformin. Results are mean ± SEM for 8–9 subjects per group. *P=0.015 vs. pre-treatment of rosiglitazone.

Relationship of serum ΔApoJ with (c) Δfasting glucose levels, (d) ΔGDR60, (e) ΔGDR120, and (f) ΔAUGg. Serum ΔApoJ levels were calculated by subtracting pre-treatment ApoJ levels from posttreatment ApoJ levels.

HHS Vulnerability Disclosure